Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 25;17(12):1584.
doi: 10.3390/ph17121584.

Danaparoid-Consensus Recommendations on Its Clinical Use

Rupert M Bauersachs  1   2 , Edelgard Lindhoff-Last  1 , Robert Klamroth  3 , Andreas Koster  4 , Marc Schindewolf  5 , Harry Magnani  6
Affiliations
Review

Danaparoid-Consensus Recommendations on Its Clinical Use

Rupert M Bauersachs et al. Pharmaceuticals (Basel). .

Abstract

(1) Background: Danaparoid sodium is a heparinoid antithrombotic that has been used for over 40 years for prophylaxis of DVT in non-HIT patients and for the treatment of heparin-induced thrombocytopenia (HIT) with and without thrombosis. This update summarises current information on its pharmacology and reviews danaparoid dose management in a broad spectrum of clinical situations, including off-label indications. (2) Methods: Evidence from published clinical studies, case reports, compassionate use of danaparoid, and spontaneously reported serious adverse events is summarised and analysed by an interdisciplinary expert group to develop a consensus on dosing regimens of danaparoid for complex clinical situations, including vulnerable patient populations. (3) Results: Dosing regimens are proposed, together with monitoring recommendations and target anti-factor Xa ranges. (4) Conclusion: In a comprehensive summary detailed interdisciplinary dosing recommendations are described to provide a basis for safe and effective use of danaparoid.

Keywords: Orgaran; anticoagulant; danaparoid; dosing; heparin-induced thrombocytopenia; heparinoid; monitoring; off-label use; thromboprophylaxis; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Danaparoid sodium in the treatment of acute HIT: multiple modes of action [24].
See this image and copyright information in PMC

References

    1. Martel N., Lee J., Wells P.S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: A meta-analysis. Blood. 2005;106:2710–2715. doi: 10.1182/blood-2005-04-1546. - DOI - PubMed
    1. Ng J.Y., D’Souza M., Hutani F., Choi P. Management of Heparin-Induced Thrombocytopenia: A Contemporary Review. J. Clin. Med. 2024;13:4686. doi: 10.3390/jcm13164686. - DOI - PMC - PubMed
    1. Hogan M., Berger J.S. Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management. Vasc. Med. 2020;25:160–173. doi: 10.1177/1358863X19898253. - DOI - PubMed
    1. Warkentin T.E. Laboratory diagnosis of heparin-induced thrombocytopenia. Int. J. Lab. Hematol. 2019;41((Suppl. S1)):15–25. doi: 10.1111/ijlh.12993. - DOI - PubMed
    1. Pishko A., Cuker A. Chapter 104—Heparin-Induced Thrombocytopenia. In: Shaz B.H., Hillyer C.D., Reyes Gil M., editors. Transfusion Medicine and Hemostasis. 3rd ed. Elsevier; Amsterdam, The Netherlands: 2019. pp. 627–640.